Case: Patents/Pleadings (Fed. Cir.)

The Supreme Court reversed the Federal Circuit’s decision in Amarin Pharma, Inc.'s patent infringement action against Hikma Pharmaceuticals USA Inc., effectively granting Hikma’s motion to dismiss for failure to state a claim of induced infringement. The Court found that Amarin failed to plausibly allege that Hikma took “active steps” to encourage infringement of Amarin’s method-of-use patents for Vascepa’s cardiovascular indication, as Hikma’s statements were either legally required, standard practice, or too vague.

This story was produced by Bloomberg Law Automation.